Aries Wealth Management Has $510,000 Stock Position in Danaher Co. (NYSE:DHR)

Aries Wealth Management lessened its position in shares of Danaher Co. (NYSE:DHR) by 2.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 2,221 shares of the conglomerate’s stock after selling 55 shares during the quarter. Aries Wealth Management’s holdings in Danaher were worth $510,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. FMR LLC boosted its stake in Danaher by 15.8% during the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after buying an additional 3,217,631 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Danaher by 3.0% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock valued at $1,417,342,000 after buying an additional 148,251 shares in the last quarter. Fisher Asset Management LLC lifted its holdings in shares of Danaher by 2.6% during the 3rd quarter. Fisher Asset Management LLC now owns 4,552,640 shares of the conglomerate’s stock worth $1,265,725,000 after acquiring an additional 116,299 shares during the period. Massachusetts Financial Services Co. MA boosted its position in shares of Danaher by 17.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after acquiring an additional 535,254 shares in the last quarter. Finally, Montrusco Bolton Investments Inc. increased its stake in Danaher by 0.6% in the fourth quarter. Montrusco Bolton Investments Inc. now owns 1,715,826 shares of the conglomerate’s stock valued at $382,936,000 after acquiring an additional 9,942 shares during the period. 79.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Danaher

In other news, SVP Brian W. Ellis sold 5,700 shares of the firm’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at $4,534,149.90. This trade represents a 21.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 11.10% of the company’s stock.

Danaher Trading Up 0.7 %

Shares of DHR opened at $203.56 on Friday. The stock’s fifty day simple moving average is $230.49 and its 200-day simple moving average is $250.28. The firm has a market capitalization of $147.03 billion, a PE ratio of 38.55, a price-to-earnings-growth ratio of 2.68 and a beta of 0.83. Danaher Co. has a 12-month low of $196.80 and a 12-month high of $281.70. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last released its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter in the prior year, the firm posted $2.09 EPS. As a group, research analysts predict that Danaher Co. will post 7.67 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.53%. The ex-dividend date was Friday, December 27th. Danaher’s dividend payout ratio is presently 20.45%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Stephens reaffirmed an “overweight” rating and set a $315.00 price objective on shares of Danaher in a report on Wednesday, October 23rd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $277.00 price target (down previously from $299.00) on shares of Danaher in a research note on Thursday, January 30th. TD Cowen increased their price objective on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Wells Fargo & Company reduced their target price on shares of Danaher from $280.00 to $240.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 30th. Finally, Guggenheim initiated coverage on shares of Danaher in a research report on Thursday, December 19th. They set a “buy” rating and a $275.00 target price for the company. Seven equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $278.00.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.